Brigatinib錠劑市場規模、佔有率和成長分析：按規格、適應症、分銷管道、最終用戶和地區分類－2026-2033年產業預測

2024 年全球Brigatinib片劑市值為 7.8 億美元，預計到 2033 年將成長至 15.7227 億美元，而 2025 年為 8.4318 億美元，在預測期（2026-2033 年）內複合年成長率為 8.1%。

全球Brigatinib尼片劑市場主要以口服ALK抑制劑治療抗藥性非小細胞肺癌（NSCLC）為特徵，特別適用於對Crizotinib等第一線療法無反應的患者。市場成長要素是對有效二線治療的需求。Brigatinib高了中樞神經系統滲透性，延長了無惡化生存期製劑的上市。此外，ALK重排肺癌在年輕人和非吸菸族群中的發生率不斷上升，也增加了對易於取得的口服療法的需求。製藥公司與學名藥生產商之間的合作旨在降低成本，並有助於市場滲透，尤其是在新興市場。

全球Brigatinib片劑市場成長要素

Brigatinib在ALK陽性和ROS1陽性非小細胞肺癌的適應症擴大，顯著提升了其治療潛力，促使腫瘤科醫師更早將藥物納入治療方案。這種適應症的擴大也提高了醫療專業人員對抗抗藥性機制的有效方案，從而促進了該藥物的普及。醫院、專科藥房和門診診所對該藥的廣泛應用推動了市場需求。此外，製藥公司為提高公眾認知度所做的努力增強了醫生的信心，並促進了該藥物的永續成長。患者權益組織也強調了該藥物良好的安全性，進一步推動了其在標準治療方案中的應用。

影響全球Brigatinib尼錠劑市場的因素

由於Brigatinib比標準化療更昂貴，這給醫院和保險公司帶來了經濟壓力，導致其納入藥品目錄的標準更加嚴格，並且需要預先核准程序。支付者通常會協商有限的報銷條件，這可能會阻礙或限制患者獲得該藥物，尤其是在醫療預算有限的地區。這種情況促使醫師考慮更具成本效益的替代方案，導致布加替尼的使用率較低，儘管其臨床療效顯著，但市場滲透率仍然較低。因此，與Brigatinib相關的經濟障礙是其廣泛應用的主要阻礙，尤其是在新興市場。

全球Brigatinib錠劑市場趨勢

全球Brigatinib片劑市場正經歷著向精準腫瘤學方向的顯著轉變，這主要得益於將全面的基因組分析整合到治療方案中。這種模式轉移凸顯了針對特定ALK和ROS1突變客製化治療方案的必要性，從而推動了伴隨診斷需求的成長，並促進了製藥公司與診斷服務供應商之間的策略合作。隨著醫療系統日益重視基於突變的治療流程，對數據基礎設施的投資，尤其是用於實現即時決策的投資，正在推動更多患者獲得Brigatinib等標靶治療。這一趨勢正在鞏固Brigatinib在全球肺癌個人化治療路徑中的地位。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 一手數據和二手數據的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 行業概覽
• 競爭環境概述

市場動態與展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

主要市場因素

• 關鍵成功因素
• 影響市場的因素
• 關鍵投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球Brigatinib錠劑市場規模：依規格

• 30mg
• 90mg
• 180mg

全球Brigatinib錠劑市場規模：依適應症分類

• ALK陽性非小細胞肺癌（NSCLC）
• 其他腫瘤適應症

全球Brigatinib錠劑市場規模：按分銷管道分類

• 醫院藥房
• 零售藥房
• 網路藥房

全球Brigatinib片劑市場規模：依最終用戶分類

• 醫院
• 癌症中心
• 專科診所

全球Brigatinib錠劑市場規模：按地區分類

• 北美洲
• 歐洲
• 亞太地區
• 其他

全球Brigatinib錠劑市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • GCC
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Takeda Pharmaceutical Company Limited
• Natco Pharma Limited
• Beacon Pharmaceuticals PLC
• Hetero Labs Limited
• Dr. Reddy's Laboratories Ltd.
• Zydus Lifesciences Limited
• MSN Laboratories Pvt. Ltd.
• Laurus Labs Limited
• Cipla Limited
• Sun Pharmaceutical Industries Limited
• Aurobindo Pharma Limited
• Intas Pharmaceuticals Ltd.
• Lupin Limited
• Teva Pharmaceutical Industries Ltd.
• Accord Healthcare Limited
• Sandoz Group AG
• Alvogen, Inc.
• Apotex Inc.
• Torrent Pharmaceuticals Ltd.
• Macleods Pharmaceuticals Ltd.

結論與建議

Global Brigatinib Tablet Market size was valued at USD 780.0 Million in 2024 and is poised to grow from USD 843.18 Million in 2025 to USD 1572.27 Million by 2033, growing at a CAGR of 8.1% during the forecast period (2026-2033).

The global market for brigatinib tablets is characterized by the oral ALK inhibitor's role in addressing treatment-resistant non-small cell lung cancer (NSCLC), particularly for patients who do not respond to first-generation therapies such as crizotinib. A major growth driver is the demand for effective second-line treatment options, as brigatinib offers enhanced central-brain penetration and extended progression-free survival rates. This has led to increased prescriptions globally, driven by positive trial results that influenced insurance coverage and clinical pathways. Additionally, the rising incidence of ALK-rearranged lung cancer among younger, non-smoking populations amplifies the need for accessible oral therapies. Collaborations between pharmaceutical companies and generic manufacturers are aimed at reducing costs, thus facilitating greater market adoption, particularly in emerging markets.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Brigatinib Tablet market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Brigatinib Tablet Market Segments Analysis

Global brigatinib tablet market is segmented by strength, indication, distribution channel, end user and region. Based on strength, the market is segmented into 30 mg, 90 mg and 180 mg. Based on indication, the market is segmented into ALK-Positive NSCLC and Other Oncology Indications. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on end user, the market is segmented into Hospitals, Cancer Centers and Specialty Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Brigatinib Tablet Market

The expansion of brigatinib's indications for treating ALK-positive and ROS1-positive non-small cell lung cancer significantly enhances its therapeutic potential, encouraging oncologists to incorporate it earlier in treatment protocols. This widened scope leads to increased prescribing rates as healthcare professionals look for effective solutions to combat resistance mechanisms. The rising adoption of this medication across hospitals, specialty pharmacies, and outpatient clinics is driving market demand. Additionally, awareness initiatives from pharmaceutical companies bolster confidence among prescribers, promoting sustained growth. Patient advocacy organizations also highlight the drug's favorable safety profile, further facilitating its integration into standard treatment practices.

Restraints in the Global Brigatinib Tablet Market

The high cost of brigatinib compared to standard chemotherapy options imposes financial constraints on hospitals and insurance companies, resulting in more stringent formulary placements and necessitating prior authorization processes. Payers frequently negotiate limited reimbursement terms, which can hinder or restrict patient access, particularly in areas with limited healthcare budgets. This circumstance leads physicians to consider more cost-effective alternatives, thereby decreasing prescription rates and hampering the drug's market penetration despite its clinical benefits. As a result, the financial barriers associated with brigatinib serve as a considerable obstacle to its widespread acceptance, particularly in burgeoning markets.

Market Trends of the Global Brigatinib Tablet Market

The Global Brigatinib Tablet market is witnessing a significant trend towards precision oncology, fueled by the integration of comprehensive genomic profiling into treatment protocols. This paradigm shift emphasizes the need for therapies tailored to specific ALK and ROS1 mutations, driving an increased demand for companion diagnostics and fostering strategic collaborations between pharmaceutical companies and diagnostic providers. As healthcare systems focus on mutation-driven treatment algorithms, investments in data infrastructure are emerging to facilitate real-time decision-making, which in turn enhances patient access to targeted brigatinib regimens. This trend solidifies brigatinib's role in personalized lung cancer care pathways across the globe.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Brigatinib Tablet Market Size by Strength & CAGR (2026-2033)

• Market Overview
• 30 mg
• 90 mg
• 180 mg

Global Brigatinib Tablet Market Size by Indication & CAGR (2026-2033)

• Market Overview
• ALK-Positive NSCLC
• Other Oncology Indications

Global Brigatinib Tablet Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Brigatinib Tablet Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Cancer Centers
• Specialty Clinics

Global Brigatinib Tablet Market Size by Region & CAGR (2026-2033)

• Market Overview
• North America
• Europe
• Asia-Pacific
• Others

Global Brigatinib Tablet Market Size & CAGR (2026-2033)

• North America (Strength, Indication, Distribution Channel, End User, Region)
  • US
  • Canada
• Europe (Strength, Indication, Distribution Channel, End User, Region)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Strength, Indication, Distribution Channel, End User, Region)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Strength, Indication, Distribution Channel, End User, Region)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Strength, Indication, Distribution Channel, End User, Region)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Natco Pharma Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beacon Pharmaceuticals PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hetero Labs Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Lifesciences Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MSN Laboratories Pvt. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Laurus Labs Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intas Pharmaceuticals Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Accord Healthcare Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz Group AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alvogen, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Apotex Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Torrent Pharmaceuticals Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Macleods Pharmaceuticals Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations